Onconetix, Inc. (ONCO) income statement
ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$3.15+0.15 (+5.00%)
Close on Nov 18, 2026Market cap $12.44MP/E –Yield –
Onconetix, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 80.4%
- Operating margin
- -2525.0%
- Net margin
- -1578.8%
- Return on equity, FY2025
- -115.5%
Financial strength
- Current ratio
- 2.21
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 201.9%
Valuation
- P/E ratio
- –
- Price to sales
- 19.26
- Price to book
- 0.92
- Dividend yield
- –
See a number that looks wrong?